Powder: -20°C for 3 years | In solvent: -80°C for 1 year
AMI1 是一种有效的、可逆的、细胞渗透性的蛋白精氨酸 N-甲基转移酶 (PRMTs) 抑制剂,对人 PRMT1 和酵母 Hmt1p 作用的 IC50值分别为 8.8 和 3.0 μM。它通过阻断肽-底物结合对 PRMTs 发挥抑制作用。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 287 | 现货 | ||
5 mg | ¥ 448 | 现货 | ||
10 mg | ¥ 663 | 现货 | ||
25 mg | ¥ 1,330 | 现货 | ||
50 mg | ¥ 1,890 | 现货 | ||
100 mg | ¥ 2,990 | 现货 | ||
500 mg | ¥ 6,730 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 547 | 现货 |
产品描述 | AMI-1 is an effective and selective Histone Methyltransferase (HMT) inhibitor (IC50: 3.0/8.8 μM, for yeast Hmt1p, and human PRMT1). |
靶点活性 | Hmt1p (yeast):3.0 μM, PRMT1 (human):8.8 μM |
体外活性 | In HeLa cells, AMI-1 inhibits methylation levels of GFP-Npl3 fusion and endogenous PRMT1-like activity. AMI-1 also inhibits nuclear receptor-mediated transactivation of a luciferase reporter in MCF7 cells. [1] In addition, AMI-1 inhibits HIV-1 RT polymerase activity with IC50 of 5 μM and inhibits DNA binding to HIV-1 RT with Kd of 2 μM. [2] In INS-1 cells, AMI-1 improves INS-1 cell function and mediates translocations of FOXO1 and PDX-1 intracellularly by regulating FOXO1 phosphorylation and methylation. [4] |
体内活性 | In chronic AIPI rats, AMI-1 (5 μg/rat) ameliorates COX2 expression and asthmatic indexes, and decreases the airway and alveoli lesions, mucus secretion, and collagen deposition in lungs. [3] |
激酶实验 | INS-1 832/13 cells are suspended in RPMI medium containing 11 mM glucose and the supplements described above. These cells are seeded at a density of 2×104?cells/well in a 96-well black plate coated with poly-D-lysine, and 1% BSA and 0.1% DMSO alone (control), palmitic acid (62.5, 125, 250, 500, and 1000 μM), oleic acid (62.5, 125, 250, 500, and 1000 μM), or TAK-875 (6.25, 12.5, 25, 50, and 100 μM) is added to the plate with 1% BSA and 0.1% DMSO, followed by culture for 72 h. After the culture, caspase 3/7 activity is measured with the Apo-one homogeneous caspase 3/7 assay according to the manufacturer's instructions. Fluorescence intensity is measured at an excitation of 485 nm and an emission at 535 nm. |
分子量 | 548.45 |
分子式 | C21H14N2Na2O9S2 |
CAS No. | 20324-87-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
H2O: 10 mg/mL (18.23 mM)
DMSO: 93 mg/mL (159.1 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
H2O / DMSO | 1 mM | 1.8233 mL | 9.1166 mL | 18.2332 mL | 45.583 mL |
5 mM | 0.3647 mL | 1.8233 mL | 3.6466 mL | 9.1166 mL | |
10 mM | 0.1823 mL | 0.9117 mL | 1.8233 mL | 4.5583 mL | |
DMSO | 20 mM | 0.0912 mL | 0.4558 mL | 0.9117 mL | 2.2792 mL |
50 mM | 0.0365 mL | 0.1823 mL | 0.3647 mL | 0.9117 mL | |
100 mM | 0.0182 mL | 0.0912 mL | 0.1823 mL | 0.4558 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
AMI-1 20324-87-2 Chromatin/Epigenetic Histone Methyltransferase protein arginine N-methyltransferases Hmt1p Inhibitor inhibit AMI1 AMI 1 PRMT1 yeast-Hmt1p PRMTs inhibitor